More on RHHBY
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $51.74 |
|
|||
| Open | $52.19 | ||||
| 52 Wk High | $35.13 | ||||
| 52 Wk Low | $28.10 | ||||
| Day High | $52.58 | ||||
| Day Low | $52.09 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,185,676 | ||||
- FDA grants priority review to Genentech's Enspryng for thyroid eye disease
- FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
- FDA accepts Genentech's application for Lunsumio and Polivy combo
- FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
- FDA grants priority review for Genentech's Tecentriq in stage III colon cancer
- FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
- Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
- Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
- Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
- U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer wit
Entities mentioned with RHHBY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Industrial Production | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
